

Almirall at a glance

Who we are

We are a global pharmaceutical company dedicated to medical dermatology. As a family-owned business, we think in generations and apply this long-term view to our contributions to people with skin conditions, placing patients at the center of our business ambitions.



Headquartered in
Barcelona

Offices around the world
14

Total employees
2,027

Country presence
102

Patients at the core

Number of products

143

Dermatology products

51

Patients we have helped with our key dermatology products¹

628,181

¹ The total number includes Klisyri® (tirbanibulin), Ilumetri® (tildrakizumab), Wynzora® (calcipotriol/betamethasone) and Seysara (sarecycline) in 2023.

Our therapeutic focus

Immune inflammatory diseases

Atopic dermatitis
Psoriasis
Hidradenitis suppurativa
Alopecia areata
Vitiligo

Non-melanoma skin cancer

Actinic keratosis
Basal cell carcinoma
Cutaneous T-cell lymphoma
Squamous cell carcinoma

Rare diseases

Autoimmune bullous diseases
Epidermolysis bullosa
Palmoplantar pustulosis

What we do

With an R&D pipeline solely focused on medical dermatology, we are at the forefront of science to develop and deliver ground-breaking, differentiated end-to-end products that address patients' needs. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose of improving patients' lives holistically.



Driven by innovation

Investment of Net Sales in R&D	Current projects in the pipeline	Current collaborations and partnerships in R&D
12.6%	15	23

Collaborative mindset

Almirall innovation hub The Hive

A novel scientific research hub located at our R&D centre

ZeClinics
(genetics research)

Centrient Pharmaceuticals
(sustainable biosynthetic pharmaceutical products)

ADmit Therapeutics
(early detection of Alzheimer)

Microomics
(DNA sequencing technologies).

Barcelona Supercomputing Center and Nostrum Biodiscovery – ARTIBAND
Generative artificial intelligence (AI)

CRG
Non-melanoma skin cancer and atopic dermatitis

Isolex
IgE-mediated disease therapies

Absci
generative AI

etherna
mRNA-based therapies for serious skin conditions

EpimAb
bispecific antibodies

Eloxx pharmaceuticals
Rare diseases

Novo Nordisk
Autoimmune dermatology diseases



Pipeline

Molecule name	Indication	Phase I	Phase II	Phase III	Registration	Geography
Sarecycline	Acne	<div></div>				China
Tirbanibulin	Actinic keratosis (LF)	<div></div>				Europa
Tildrakizumab	Psoriatic arthritis	<div></div>				Europa
Lebrikizumab	Atopic Dermatitis pediatric	<div></div>				Europa
Anti-IL-21 mAb	Autoimmune dermatology	<div></div>				Worldwide
Anti-IL-1RAP mAb	Autoimmune dermatology	<div></div>				Worldwide
IL-2muFc*	Autoimmune disease	<div></div>				Worldwide
ZKN-013	Rare dermatology	<div></div>				Worldwide

*Worldwide ex- Greater China



Our 2030 Sustainability Strategy

Act for impact is a strategic factor in our plan to make a meaningful and lasting difference in society and the environment while upholding its core principles of transparency, responsibility, ethics, and compliance.

GOING BEYOND FOR A GREATER IMPACT

Planet

Take bold action on climate through our science-led **Net Zero Emissions Strategy**, delivering our energy decarbonisation, sustainable mobility and sustainable procurement plans. Promote actions towards **water stewardship, circular economy, and nature protection**.



People

Implement a **Global Diversity, Equity and Inclusion Plan**, enhance our **Talent Management** to unleash our employees full potential, deploy our corporate holistic **Wellbeing Programme** and consolidate a Corporate **Volunteering Programme**.



Patients

Strengthen our commitment to patients through our **Patient Organisations Engagement Plan** with a special focus on our derma patient's wellbeing. Reinforce a **Patient Centric Mindset** across all Almirall and prioritize the needs of patients, putting them at the core of our decisions.



Partners

Deploy our **sustainable procurement programme**, through an enhanced **Supplier Risk Management Process**, implementing tools and platforms to support the process, ensuring effective governance and reinforcing **sustainability-related aspects** in the relationship with our value chain.



Principles

Further integrate sustainability into the company's strategy and governance, increase our transparency by continuing **to report to best-in-class ESG** rating agencies and ensure an **ethical culture and mindset**, being **accountable** in all our actions.



External ESG Initiatives:

